Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 2
1995 2
1996 1
1997 3
1998 3
1999 2
2000 3
2001 1
2002 1
2003 1
2004 1
2005 2
2006 2
2007 4
2008 4
2009 4
2010 4
2011 5
2012 2
2013 3
2014 4
2015 7
2016 7
2017 6
2018 11
2019 7
2020 8
2021 10
2022 13
2023 10
2024 9
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Wakita S, et al. Among authors: uoshima n. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. Blood Adv. 2022. PMID: 34448807 Free PMC article.
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study.
Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S. Mitani K, et al. Among authors: uoshima n. Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959. Blood Adv. 2024. PMID: 38134300 Free PMC article. Clinical Trial. No abstract available.
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S. Jang JH, et al. Among authors: uoshima n. Br J Haematol. 2021 Jan;192(1):190-199. doi: 10.1111/bjh.17190. Epub 2020 Nov 5. Br J Haematol. 2021. PMID: 33152120 Free PMC article. Clinical Trial.
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Wakita S, et al. Among authors: uoshima n. Cancer Sci. 2023 Apr;114(4):1297-1308. doi: 10.1111/cas.15720. Epub 2023 Jan 27. Cancer Sci. 2023. PMID: 36610002 Free PMC article.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: uoshima n. Ann Hematol. 2024 Dec;103(12):5681-5690. doi: 10.1007/s00277-024-05705-z. Epub 2024 Mar 16. Ann Hematol. 2024. PMID: 38492020
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, Isa R, Tsukamoto T, Mizutani S, Uchiyama H, Kaneko H, Uoshima N, Kawata E, Taniwaki M, Shimura Y, Kuroda J. Ide D, et al. Among authors: uoshima n. Int J Hematol. 2024 Jun;119(6):697-706. doi: 10.1007/s12185-024-03750-y. Epub 2024 Mar 16. Int J Hematol. 2024. PMID: 38492199
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: uoshima n. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.
Shimazu Y, Kanda J, Takakuwa T, Onda Y, Fukushima K, Hotta M, Fuchida SI, Uoshima N, Shimura Y, Tanaka H, Ohta K, Shibayama H, Kosugi S, Yagi H, Yoshihara S, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: uoshima n. Ann Hematol. 2024 Dec;103(12):5639-5649. doi: 10.1007/s00277-024-05934-2. Epub 2024 Aug 21. Ann Hematol. 2024. PMID: 39167179
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Nakaya A, Shibayama H, Uoshima N, Yamamura R, Yoshioka S, Imada K, Shimura Y, Hotta M, Matsui T, Kosugi S, Hanamoto H, Uchiyama H, Yoshihara S, Fuchida SI, Onda Y, Tanaka Y, Ohta K, Matsuda M, Kanda J, Yoko A, Kiyota M, Kawata E, Takahashi R, Fukushima K, Tanaka H, Yagi H, Takakuwa T, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Nakaya A, et al. Among authors: uoshima n. Leuk Res Rep. 2023 Nov 17;20:100395. doi: 10.1016/j.lrr.2023.100395. eCollection 2023. Leuk Res Rep. 2023. PMID: 38076634 Free PMC article.
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T. Hidaka M, et al. Among authors: uoshima n. Jpn J Clin Oncol. 2024 Feb 7;54(2):153-159. doi: 10.1093/jjco/hyad156. Jpn J Clin Oncol. 2024. PMID: 37986553 Free PMC article.
126 results